Connect Biopharma Holdings Ltd., a clinical-stage biopharmaceutical company focused on inflammatory diseases, has announced the initiation of Phase 2 Seabreeze STAT studies. These studies are evaluating rademikibart as an adjunct treatment for acute exacerbations in patients with asthma and chronic obstructive pulmonary disease (COPD). The company has already presented positive data supporting rademikibart's potential efficacy and safety at major medical meetings, specifically ATS 2025 and EAACI 2025. Additionally, Connect Biopharma has submitted a new drug application for rademikibart for the treatment of atopic dermatitis $(AD)$ to China's National Medical Products Administration via Simcere, their exclusive licensee in Greater China. This move is part of Connect Biopharma's strategic efforts to expand its market presence and enhance investor engagement by transitioning from an American Depositary Receipt program to directly listing ordinary shares on Nasdaq.